{"id":"doi:10.3389/fimmu.2022.816005","kind":"review","title":"CD3 + CD4 - CD8 - (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer","authors":["Wu Z","Zheng Y","Sheng J","Han Y","Yang Y","Pan H","Yao J"],"author_count":7,"year":2022,"published":"2022-02-10","venue":"Frontiers in immunology","cited_by":224,"doi":"10.3389/fimmu.2022.816005","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3389/fimmu.2022.816005","archive_url":"https://space-kitty.com/papers/doi:10.3389/fimmu.2022.816005","updated":null,"pmid":"35222392","pmcid":"PMC8866817","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC8866817/pdf","abstract":"The crucial role of CD4 + and CD8 + T cells in shaping and controlling immune responses during immune disease and cancer development has been well established and used to achieve marked clinical benefits. CD3 + CD4 - CD8 - double-negative (DN) T cells, although constituting a rare subset of peripheral T cells, are gaining interest for their roles in inflammation, immune disease and cancer. Herein, we comprehensively review the origin, distribution and functions of this unique T cell subgroup. First, we focused on characterizing multifunctional DN T cells in various immune responses. DN regulatory T cells have the capacity to prevent graft-versus-host disease and have therapeutic value for autoimmune disease. T helper-like DN T cells protect against or promote inflammation and virus infection depending on the specific settings and promote certain autoimmune disease. Notably, we clarified the role of DN tumor-infiltrating lymphocytes and outlined the potential for malignant proliferation of DN T cells. Finally, we reviewed the recent advances in the applications of DN T cell-based therapy for cancer. In conclusion, a better understanding of the heterogeneity and functions of DN T cells may help to develop DN T cells as a potential therapeutic tool for inflammation, immune disorders and cancer.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"CD3 + CD4 - CD8 - (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer\" by Wu Z, Zheng Y, Sheng J et al., https://doi.org/10.3389/fimmu.2022.816005, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}